XERIS BIOPHARMA HOLDINGS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 27.57 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 10.97M shares, a 74.61% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 10.97M shares, a 77.75% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 43.22M shares, a 13.60% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-09-30 was 49.31M shares.
- XERIS BIOPHARMA HOLDINGS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 12.44M shares, a 74.74% decline from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 49.25M shares, a 9.24% increase from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 45.08M shares, a 16.38% increase from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 38.73M shares, a 10.17% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 27.57M shares 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 10.97M shares 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 12.44M shares 10-K · filed 2026-03-02 | |||
| 2025-09-30 | 10.97M shares 10-Q · filed 2025-11-06 | 33.18M shares 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | 38.28M shares 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | 43.22M shares 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 49.25M shares 10-K · filed 2026-03-02 | |||
| 2024-09-30 | 49.31M shares 10-Q · filed 2025-11-06 | 49.31M shares 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | 50.01M shares 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | 50.02M shares 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 45.08M shares 10-K · filed 2026-03-02 | |||
| 2023-09-30 | 43.98M shares 10-Q · filed 2024-11-08 | |||
| 2023-06-30 | 43.69M shares 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | 43.91M shares 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 38.73M shares 10-K · filed 2025-03-06 | |||
| 2022-09-30 | 38.83M shares 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 39.17M shares 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | 43.98M shares 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | 35.16M shares 10-K · filed 2023-03-08 | |||
| 2021-09-30 | 22.59M shares 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | 22.49M shares 10-Q · filed 2022-08-10 | |||
| 2021-03-31 | 22.69M shares 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | 21.23M shares 10-K · filed 2022-03-11 | |||
| 2020-09-30 | 33.91M shares 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |